secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001213900-24-056571
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital terminates business combination with Longevity Biomedical; SPAC seeks new target
--------------------------------------------------------------------------------

- Merger agreement terminated effective June 26, 2024, by mutual agreement of Denali and Longevity Biomedical.
- Original merger agreement was entered January 25, 2023; no reason for termination specified.
- Denali and its sponsor will pursue alternative initial business combination; S-4 registration to be withdrawn.
- Ancillary agreements also automatically terminate; certain customary survival provisions remain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024056571/0001213900-24-056571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024056571/ea0208645-8k_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-056571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer